Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

18F-Flourodeoxy glucose PET–computed tomography in testicular carcinoma

diagnostic and prognostic value

Soydal, Cigdema; Araz, Minea; Urun, Yukselb; Gulpinar, Basakc; Nak, Demeta; Ozkan, Elgina; Kucuk, Nuriye Ozlema

doi: 10.1097/MNM.0000000000001093
Original Articles
Buy

Aim This study aims to assess the diagnostic role of 18F-FDG PET/computed tomography in primary staging and restaging of testicular cancer in comparison with contrast-enhanced diagnostic thoracic-abdominopelvic computed tomography.

Material and method Thirty-two consecutive male patients with testicular carcinoma (median age: 29, min–max: 17–65) who were referred to the nuclear medicine department for 18F-FDG PET/computed tomography were retrospectively included in the study. Patients were evaluated based on the 18F-FDG PET/computed tomography indications and germ cell tumor subtypes.

Results On patient-based analysis, overall sensitivity, specificity, PPV, NPV and accuracy of 18F-FDG PET/computed tomography were 71%, 100%, 100%, 30% and 75%. On lesion-based analysis, for evaluation of lymph node metastasis they were 76%, 100%, 100%, 57% and 81%, and for detection of distant metastasis 85%, 100%, 100%, 90% and 93%, respectively. Median SUVmax for seminomas were calculated as 14.2 and for nonseminomas 7.8 (P = 0.62) Mean time to progression and overall survival were calculated as 76.6 ± 10.7 and 111 ± 7.5 months, respectively. Mean overall survival and time to progression for PET-positive and negative groups was not found significant (P = 0.69 and P = 0.81). The only significant factor in predict overall survival was the presence of distant organ metastases in PET/computed tomography (124.6 ± 5.2 vs. 78.7 ± 14.0 months, P = 0.02).

Conclusion In this single-center experience with a limited number of patients, 18F-FDG PET/computed tomography appears to have a value of staging and restaging for both seminomatous and non-seminomatous GCTs.

Departments of aNuclear Medicine

bMedical Oncology

cRadiology, Ankara University Medical Faculty, Ankara, Turkey

Received 29 May 2019 Accepted 9 August 2019

Correspondence to Cigdem Soydal, MD, FEBNM, Department of Nuclear Medicine, Ankara University Medical School, 06590 Cebeci, Ankara, Turkey, Tel: +90 3125956732; fax: +90 3123620897; e-mail: csoydal@yahoo.com

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.